During cerebral ischemia, the coenzyme NAD+ sits at the intersection of energy failure and DNA-damage signaling. This article reviews what preclinical research reports about NAD+ metabolism, PARP overactivation, and sirtuin pathways in neuronal survival — and where the evidence stops. All discussion refers to laboratory and animal models, not human use.

Why NAD+ sits at the center of ischemic neuronal death

Neurons carry a high and continuous energy demand and hold little metabolic reserve. When cerebral blood flow drops, oxygen and glucose delivery falls within seconds, and the electron transport chain can no longer regenerate ATP efficiently. Nicotinamide adenine dinucleotide (NAD+) is a central redox cofactor in this machinery: it accepts electrons during glycolysis and the TCA cycle and hands them to the respiratory chain, cycling between its oxidized (NAD+) and reduced (NADH) forms. Beyond redox chemistry, NAD+ is also a consumable substrate for signaling enzymes, so its intracellular pool can be spent, not merely interconverted.

Because of this dual role, the size of the NAD+ pool becomes a useful readout of neuronal bioenergetic state under stress. In cultured neurons and rodent stroke models, investigators have repeatedly reported that a decline in NAD+ tracks closely with the loss of mitochondrial membrane potential and the appearance of cell-death markers.⁵ Reviews of poly(ADP-ribose) metabolism in the brain describe how the coordinated turnover of NAD+ by synthesizing and consuming enzymes is central to whether tissue in the ischemic penumbra recovers or progresses to infarction.¹

The practical consequence for researchers is that NAD+ is not a peripheral metabolite in ischemia; it is a hub where energy metabolism, oxidative stress, and DNA-damage signaling converge. That convergence is why so much experimental work on neuronal survival during reduced blood flow returns to NAD+ handling.

The PARP–NAD+ axis and parthanatos

The most heavily studied route connecting NAD+ depletion to neuronal death runs through poly(ADP-ribose) polymerase-1 (PARP-1). PARP-1 normally acts as a DNA-strand-break sensor: when it detects oxidative DNA damage — abundant during ischemia and reperfusion — it becomes catalytically active and builds poly(ADP-ribose) (PAR) polymers on nuclear proteins. Each unit of PAR is assembled from NAD+, so sustained PARP-1 activity draws down the cytosolic NAD+ pool.¹

Under severe, prolonged damage this becomes maladaptive. In preclinical work, PARP-1 overactivation is described as a primary cause of mitochondrial depolarization and delayed neuronal death, in part because NAD+ depletion blocks glycolytic ATP production and starves mitochondria of substrate.² The PAR polymer itself is not inert: it acts as a death signal that promotes the release of apoptosis-inducing factor (AIF) from mitochondria and its translocation to the nucleus, where it drives large-scale DNA fragmentation. This caspase-independent cascade has been named parthanatos.³

Genetic studies in focal ischemia sharpen the picture. In mice subjected to transient middle cerebral artery occlusion, deletion of PARP-1 or PARP-2 markedly reduced infarct volume at three days and suppressed the ischemia-induced nuclear accumulation of AIF, implicating both enzymes in the AIF translocation step and the resulting injury.⁴ Complementary excitotoxicity experiments show that NAD+ decline and PAR accumulation are relatively early events, preceding the appearance of necrotic and DNA-strand-break markers — consistent with NAD+ loss being upstream of, rather than merely coincident with, neuronal death.⁵

This mechanistic chain — ischemia → oxidative DNA damage → PARP-1 overactivation → NAD+ depletion and PAR signaling → AIF translocation → cell death — is why interventions in this literature aim either to restrain PARP overconsumption or to replenish the NAD+ that PARP has spent.

Sirtuins as NAD+-dependent survival switches

NAD+ is not consumed only by PARPs. Sirtuins, a family of NAD+-dependent deacetylases (SIRT1–SIRT7), also depend on the coenzyme, and they behave as sensors of the cellular redox and energy state. This creates a competitive dynamic: when NAD+ is scarce, sirtuin-mediated signaling can be constrained at the same time PARP is depleting the pool.⁵

SIRT1 and the AMPK axis

In ischemic-stroke models, SIRT1 has been linked to survival signaling through the liver kinase B1 (LKB1)–AMP-activated protein kinase (AMPK) pathway. When the NAD+-synthesizing enzyme NAMPT is overexpressed, neuronal NAD+ rises, SIRT1 deacetylates LKB1, and downstream AMPK activation is reported to support neuronal survival under ischemic stress; the neuroprotective effect was abolished in SIRT1- and AMPK-deficient animals.⁶ Broader reviews position SIRT1 activation as a candidate neuroprotective strategy across cerebrovascular models, while noting the effects are context-dependent.¹⁰

SIRT3 and mitochondrial quality

SIRT3, the principal mitochondrial sirtuin, deacetylates metabolic and antioxidant enzymes inside the organelle. In global cerebral ischemia, NAD+ precursor administration normalized mitochondrial NAD+ pools, reduced acetylation of the antioxidant enzyme SOD2, lowered reactive oxygen species, and limited mitochondrial fragmentation — effects that were dependent on SIRT3 in knockout experiments.⁷ The sirtuin story is not uniformly simple, however: one experimental stroke study found neuroprotection in SIRT3-knockout mice that appeared to be mediated by a compensatory rise in SIRT1, a reminder that individual family members can behave differently across models.⁸

Replenishing NAD+: precursors and NAMPT in stroke models

If NAD+ depletion contributes to injury, does restoring it change outcomes in the laboratory? A consistent body of preclinical work reports that raising brain NAD+ — pharmacologically, enzymatically, or with precursors — is associated with smaller infarcts and improved neuronal metabolic readouts. The table below summarizes representative findings; note that all are animal or cell-culture studies.

Two mechanistic themes recur across these reports. First, the timing of intervention matters: benefits are most evident when NAD+ is restored early relative to ischemia onset, consistent with the idea that NAD+ collapse is an early, upstream event.⁵ Second, the downstream readouts — ATP recovery, reduced oxidative stress, preserved mitochondrial morphology — point back to the same sirtuin- and mitochondria-centered pathways discussed above rather than to a single isolated target.⁹ Because mitochondrial function is so central to these outcomes, researchers studying energy-metabolism intersections sometimes pair NAD+ work with other mitochondrially targeted tools such as the mitochondrial-derived peptide MOTS-C, though those are distinct molecules with their own separate literature.

Clarifying the “peptide NAD+” framing

A point of terminology deserves emphasis, because it is often blurred in secondary sources. NAD+ is a dinucleotide coenzyme — two nucleotides (nicotinamide mononucleotide and an adenine nucleotide) joined by phosphate groups. It is not a peptide, and it is not built from amino acids. Phrases like “peptide-linked NAD+” conflate two different chemical classes.

Where peptides and proteins do enter the picture is on the enzymatic side. The machinery that synthesizes, consumes, and responds to NAD+ — NAMPT and NMNAT in the salvage pathway, PARP-1/PARP-2, and the sirtuin deacetylases — are all proteins.¹⁶ Manipulating those proteins (for example, by overexpressing NAMPT) changes NAD+ availability, which is why enzyme-focused and coenzyme-focused strategies are studied side by side. For researchers, the useful mental model is a metabolic network: NAD+ is the shared currency, and the proteins around it set the exchange rate. Describing the research accurately means keeping the coenzyme and its enzymes conceptually distinct, even when they are experimentally linked.

What the evidence does — and does not — establish

The preclinical literature makes a coherent case that NAD+ handling shapes neuronal fate during ischemia in model systems: depletion via PARP overactivation is tied to energy failure and parthanatos, and repletion via precursors or NAMPT is associated with smaller infarcts and better mitochondrial readouts in rodents and cultured cells.²⁷⁹ That is a strong mechanistic rationale, and it is internally consistent across independent laboratories.

Several important limits remain. The findings are drawn overwhelmingly from young, otherwise-healthy animals and simplified cell cultures that do not capture the age, comorbidity, and heterogeneity of human stroke. Sirtuin effects are model-dependent and sometimes contradictory, as the SIRT3-knockout data illustrate.⁸ Timing windows that work in rodents are narrow and may not translate. And historically, many neuroprotective mechanisms that reduced infarct volume in animals have failed to reproduce clinical benefit. None of the NAD+-modulating approaches discussed here is an approved therapy for stroke or any other condition as of 2026, and rigorous human efficacy data are lacking. The appropriate reading is that NAD+ metabolism is a well-motivated research target, not a settled intervention.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.